top of page
STAIR XII Badge 1.0.jpg

"INTEGRATING CYTOPROTECTION AND REPERFUSION"

 New Perspectives on Expanding and Combining Research and Development of Acute Stroke Treatment Drugs and Devices

 

DAY 1 THURSDAY MORNING, MARCH 27 

All Meals are served in Salons 1-3 Adjacent to the Ballroom

* Ballroom – Location of all General Sessions – Main Floor of Hotel

* Presentations are 10 minutes each.

7:00 – 8:00   Full Breakfast Provided  -- Salons 1-3

8:00 – 8:40   WELCOME AND OPENING REMARKS  -- Ballroom

SETTING THE STAGE​

      Welcome to STAIR XIII - Co-chairs Greg Albers and Marc Fisher

      "A Future Vision of Acute Stroke Research and Treatment" - Jeff Saver

8:40 – 10:25    SESSION 1   WHAT HAVE WE LEARNED FROM RECENT ACTUE STROKE TRIALS?

Session Chairs:  Jim Grotta and Opeolu Adeoye

  • Lessons learned from ESCAPE, NEXT and FRONTIER; Next steps for Cytoprotection – Michael Hill

  • Implications of TIMELESS, TRACE III, ARAMIS and TEMPO 2 – Carol Xiong

  • Large EVT core studies: Is there an outer limit? – Jeremy Heit

  • Large core medical therapy, insights from CHARM – Kevin Sheth

ROUNDTABLE PANEL DISCUSSION: Yilong Wang, Steve Warach, plus others TBD

 

10:40 – 10:55       Refreshment Break  -- Foyer Outside of Ballroom

 

10:55 – 12:25   SESSION 2    CYTOPROTECTION - RENEWED PROMISE AND NEW APPROACHES

Session Chairs:  Eva Mistry and Mike Tymianski

  • What are the most promising cytoprotectant agents and neuronal/glial pathways? - Marion Buckwalter

  • Can we define different types of cerebroprotection depending on the time of intervention – Pat Lyden

  • Should we target no reflow/residual perfusion lessions following EVT?– Thanh Nguyen

  • How can we evaluate cytoprotective effects in phase II trials as did Revalesio and ApT – Marc Ribo

ROUNDTABLE PANEL DISCUSSION: Marcelo Rocha, Liz Dallimore, Renyu Liu, plus others TBD

 

12:25 – 1:20   LUNCH PROVIDED  -- Salons 1-3

 

DAY 1  THURSDAY AFTERNOON -- Ballroom  

 

1:25 – 2:45  SESSION 3   INTEGRATING CYTOPROTECTION AND REPERFUSION: TRIALS AND PLATFORMS

Session Chairs:  Andrei Alexandrov and Hooman Kamel

  • Key Considerations for Integrating Drug and Device Trials – Larry Wechsler

  • Ongoing Cytoprotective Trials: Study Designs highlighting major trials – David Liebeskind

  • EVT Trials; Recent (ESCAPE, MeVo, DISTAL) and low NIHSS subjects – Urs Fischer

  • STEP / ACT-GLOBAL  – Pooja Khatri

ROUNDTABLE PANEL DISCUSSION:  A.J. Wakhloo, Jordon Elm, plus others TBD

 

2:45 – 3:45   SESSION 4  EXPEDITING URGENT EVALUATION & TREATMENT OF ACUTE STROKE

Session Chairs: Edward Jauch and Raul Nogueira

  • AI Impact on acute stroke transfer, treatment and trials – Greg Albers

  • Surging DOAC usage and Implications for Acute Stroke Research  – Jennifer Frontera

  • Detecting ICH and LVO in the ambulance – Wade Smith

  • Prehospital Therapy: FRONTIER, iNTERACT4, MSU – Johanna Ospel

ROUNDTABLE PANEL DISCUSSION: Shadi Yaghi, Lucy He, plus others TBD

3:45 – 4:00       Refreshment Break  -- Foyer Outside of Ballroom

 

4:00 – 5:00    SESSION 5   REGULATORY PERSPECTIVES ON KEY CLINICAL TRIAL ISSUES  

Session Chairs: Greg Albers and Marc Fisher

  • New Approaches at the FDA – FDA Representatives

  • FDA Panel (CDER & CDRH) Answers to Stroke Community Questions pre-submitted and audience engagement

ROUNDTABLE PANEL DISCUSSION:  FDA: Heather Fitter, Shawna Cutting (CDER), Xiaolin Zheng (CDRH)

 

6:30 – 7:30    SPONSORED RECEPTION -- Studio B – Main Floor of Hotel

 

7:30 – 9:00    DINNER BANQUET   -- Salons 1-3

FOLLOWED BY SPECIAL PRESENTATION

Walter Koroshetz, NINDS Director   

Dr. Koroshetz will be interviewed by Lee Schwam with Audience Participation

DAY 2  FRIDAY MORNING, MARCH 28 

7:00 – 8:00   FULL BREAKFAST PROVIDED  -- Salons 1-3

8:00 – 10:30   WORKSHOPS TO DEVELOP RECOMMENDATIONS 

 * All Participants - Please Report Directly to Your Assigned Workshop at 8:00 AM 

 * All Workshops held in Studios B, D and F on Main Floor of Hotel

 * Participants divide into three groups according to their topic choice

 * Each group will develop recommendations on their selected topic

WORKSHOP 1:   OPTIMIZING REPERFUSION TRIALS

Studio - D     Facilitators – Chair: Bruce Campbell, Co-chair: David Fiorella, Recorder: TBD 

                  

WORKSHOP 2:   PRIORITIES FOR CYTOPROTECTION TRIALS

Studio - B     Facilitators – Chair: Sean Savitz, Co-chair: Edgar Samaniego , Recorder: Johannes Boltz

WORKSHOP 3:   NEW TRIAL DESIGNS AND STRATEGIES INCLUDING AI AND PLATFORMS

Studio - F      Facilitators – Chair: Joe Broderick, Co-chair: Scott Kasner, Recorders: Yasmin Aziz & Paul Wechsler

10:30 – 10:45   Refreshment Break 

 

10:45 – 12:00    WORKSHOP CHAIRS PRESENT RECOMMENDATIONS TO FULL ASSEMBLY

Ballroom        Drafting of consensus statements is initiated – Chaired by Greg Albers and Marc Fisher

12:00 – 12:15      CLOSING COMMENTS AND ADJOURNMENT

STAIR MISSION STATEMENT

The STAIR Consensus Conferences, via a collaboration of medical academia, the healthcare industry and government agencies, are intended to advance and accelerate stroke research to ultimately result in improved stroke acute treatment, care and prevention. To achieve this goal, STAIR will:

  •   Develop new approaches to overcome barriers impeding stroke drug and device development

  •   Identify, clarify and communicate the implications of new research to the stroke field

  •   Publish STAIR Workshop recommendations developed by participants which address these concerns

  •   Promote adoption of STAIR solutions by research, industry, clinical and government communities

The information contained in this website reflects opinions of STAIR participants regarding the process of conducting research and development into existing, new and prospective drugs and devices for the treatment of stroke. The information is not intended to be a substitute for rigorous independent testing and development of individual compounds and devices by research sponsors, nor should the information and opinions be construed as official government regulations or official interpretations of government regulations. All government regulations and their applications to specific research studies and clinical trials are subject to individual deliberations between study sponsors and government agencies. The information contained in this website is not intended to be a substitute for sound medical advice, clinical judgment or informed treatment decisions.

STAIR® is a Registered Trademark of The Stroke Group.   

© 2025 The Stroke Group

bottom of page